Cell line development involves the screening of thousands of clones in an effort to find the few optimal clones that are stable, grow as expected, and produce high yields of the bioproduct. The time it takes from engineering an optimal cell line to the production of the target biologic can be prohibitive and may differ from molecule to molecule. While expression-level analysis like titer screening is carried out early, other critical quality attributes (CQAs) such as glycan characterization are often assessed only later in the development process due to a lack of appropriate and high-throughput analytical techniques that can be used to perform quick screens. Commonly used methods for antibody quantitation require either specialized instrumentation and skilled personnel (e.g., high-performance liquid chromatography) or are time-consuming (e.g., enzyme-linked immunosorbent assays). This application note highlights how the Octet platform helps address these challenges.
Fill out the form below to read the Special Report and learn more about the Octet platform now.